ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

elecoglipron

Also written as “Elecoglipron”, “AZD5004” and “ECC5004”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Heart Failure · Renal Insufficiency, Chronic · Renal Insufficiency, led by 2 companies.

Drug pageElecoglipron: every studyAll 25 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 18, 202626 company-led studies, 11 open or runningLicense: Eccogene → AstraZeneca, Nov 2023Next primary completion: Nov 18, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca2211 open or runningphase 3since Jun 18, 2026Aug 13, 2024Nov 18, 2026phase 1 · NCT07723833
Eccogeneits history only40 open or runningphase 1since Dec 8, 2022Dec 8, 2022none ahead
  • Named in AstraZeneca’s own pipeline as elecoglipron, phase 3, as of Oct 30, 2026 (source).

Also a collaborator on its studies: Parexel and Quotient Sciences.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

  • LicenseAstraZeneca licensed it from Eccogene, for everywhere outside China, where the two develop and sell it together.Announced Nov 9, 2023 · Source: AstraZeneca, Nov 9, 2023

History and studies of AstraZeneca only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 1 earlier study, Aug 13, 2024 to Aug 13, 2024.

  1. Nov 9, 2023AstraZeneca licensed it from EccogeneLicenseEverywhere outside China, where the two develop and sell it together · announced · AstraZeneca
  2. Aug 28, 20242 phase 2 studiesNCT06579105, NCT06579092
  3. Oct 29, 2024Phase 1 study in Diabetes Mellitus, Type 2NCT06703658 · 35 enrolled · Japan
  4. Dec 16, 20242 phase 1 studiesNCT06742762, NCT06813781
  5. Feb 13, 2025Named elecoglipronINNProposed as its International Nonproprietary Name in WHO's List 132 · before, AZD5004, ECC5004
  6. Feb 27, 2025Phase 1 study in Healthy ParticipantsNCT06857695 · 8 enrolled · United Kingdom
  7. Apr 28, 2025Phase 1 study in ObesityNCT06948747 · 49 enrolled · United States
  8. May 21, 2025Phase 1 study in Diabetes Mellitus, Type 2NCT06996886 · 16 enrolled · United States
  9. Feb 26, 2026Phase 1 study in Diabetes Mellitus, Type 2NCT07444424 · 32 enrolled · Japan
  10. Mar 3, 2026Phase 1 study in Diabetes Mellitus, Type 2NCT07455825 · 65 enrolled · United States
  11. Apr 10, 2026Phase 1 study in Diabetes Mellitus, Type 2NCT07534592 · 48 enrolled · United States
  12. Jun 18, 20266 phase 3 studiesPhase 3 reachedNCT07664553, NCT07662213, NCT07662135 and 3 more
  13. Jul 20, 2026Phase 1 study in Diabetes Mellitus, Type 2NCT07723833 · 152 planned · United States
  14. Aug 3, 20263 phase 3 studiesNCT07761117, NCT07753993, NCT07775404
  15. Oct 1, 2026Primary completion moved from 2027-06-04 to 2028-04-06Date moved laterphase 3 · +10 months · NCT07775404
  16. Nov 10, 2026Primary completion moved from 2026-10-01 to 2027-01-25Date moved laterphase 1 · +4 months · NCT07534592

Ahead

  1. Nov 18, 2026Primary completion: phase 1 study in Diabetes Mellitus, Type 2NCT07723833
  2. Jan 25, 2027Primary completion: phase 1 study in Diabetes Mellitus, Type 2NCT07534592
  3. Apr 6, 2028Primary completion: phase 3 study in ObesityNCT07775404
  4. May 23, 2028Primary completion: phase 3 study in Diabetes Mellitus, Type 2NCT07664553

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 22 AstraZeneca leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07775404Obesity · China, Hong Kong, Malaysia and more3RecruitingApr 6, 2028351
NCT07753993Renal Insufficiency, Chronic · United States, Argentina, Australia and more3RecruitingOct 4, 20307,000
NCT07761117Heart Failure · United States, Argentina, Australia and more3RecruitingSep 3, 20296,950
NCT07723833Diabetes Mellitus, Type 2 · United States1RecruitingNov 18, 2026152
NCT07667803Weight Management · United States, Argentina, Australia and more3RecruitingJul 31, 20284,500
NCT07664553Diabetes Mellitus, Type 2 · United States, Australia, Bulgaria and more3RecruitingMay 23, 2028600
NCT07662213Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more3RecruitingMay 23, 20281,200
NCT07662135Diabetes Mellitus, Type 2 · United States, Bulgaria, China and more3RecruitingJul 13, 2028900
NCT07662109Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more3RecruitingJul 5, 20282,000
NCT07662044Diabetes Mellitus, Type 2 · United States, Argentina, China and more3RecruitingJul 14, 2028800
NCT07534592Diabetes Mellitus, Type 2 · United States1Active, not recruitingJan 25, 202748
NCT07455825Diabetes Mellitus, Type 2 · United States1CompletedJun 1, 202665
NCT07444424Diabetes Mellitus, Type 2 · Japan1CompletedJul 2, 202632
NCT06996886Diabetes Mellitus, Type 2 · United States1CompletedJul 15, 202516
NCT06948747Obesity · United States1CompletedOct 3, 202549
NCT06857695Healthy Participants · United Kingdom1CompletedMay 5, 20258
NCT06813781Hepatic Impairment · United States1CompletedOct 2, 202533
NCT06742762Renal Insufficiency · United States1CompletedApr 20, 202516
NCT06703658Diabetes Mellitus, Type 2 · Japan1CompletedMar 13, 202535
NCT06579105Diabetes Mellitus, Type 2 · United States, Canada, Germany and more2CompletedDec 19, 2025406
NCT06579092Obesity · United States, Australia, Canada and more2CompletedNov 21, 2025310
NCT06555822Obesity · United States1CompletedMar 6, 202531

How it is read

Names in the registry

  • “Elecoglipron”, 10 entries
  • “AZD5004”, 10 entries
  • “ECC5004”, 3 entries
  • “Elecoglipron Reference Formulation Dose A”, 1 entry
  • “Elecoglipron Reference Formulation Dose B”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.